Skip to content

Study of Glaucoma Treatment With Food Additives

Treatment of Glaucomatous Neuropathy With Food Additives

Status
Terminated
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00196677
Enrollment
25
Registered
2005-09-20
Start date
2005-09-30
Completion date
2008-10-31
Last updated
2009-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucomatous Neuropathy

Brief summary

The purpose of this study is to determine if certain food additives are effective in the treatment of glaucoma, improving and reversing the progress of the disease.

Detailed description

Glaucomatous neuropathy is a condition that worsens with time causing atrophy of the optic nerve and narrowing of the visual field which may culminate in blindness. The treatment tested in the trial employs certain food additives intended to reverse this pathology.

Interventions

DRUGVitamins, minerals and medical herbs

Sponsors

Future Products Management
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Stable open angle glaucoma - with equilibrated eye internal pressure * Above the age of 50 years and have severe damage that does not progress to the vision field in the upper and lower half. Scoring of the vision field will be made according to the Agis study instructions.

Exclusion criteria

* Eye diseases excluding past cataract operation * Allergy to one of the components in the preparation * Deterioration in the vision field in the last year * Kidney diseases, gastrointestinal (G.I.) tract, liver diseases, coagulation problems and thyroid diseases * Persons who take steroids * Diabetics or unbalanced hyperglycemia * Autoimmune diseases * Hypertension (not responding to treatment) * Psychiatric treatment with drugs, psychiatric pathologies * Pregnancy * Ability to take more than 3 pills per day regularly * Smoking

Design outcomes

Primary

MeasureTime frame
Improvement in vision field (Protocol24) in a Humphrey's instrument. Scoring according to the Agis study

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026